TG Therapeutics Presents BRIUMVI Data at Key Conference
TG Therapeutics, Inc. (NASDAQ: TGTX) is excited to announce their recent data presentations highlighting BRIUMVI® (ublituximab-xiiy) during an important conference focused on multiple sclerosis (MS). The presentations took place at a key annual meeting organized by the Consortium of Multiple Sclerosis Centers. This event enabled the company to showcase groundbreaking research revolving around their innovative treatments for relapsing forms of multiple sclerosis (RMS).
Highlights of the Presentations
During the conference, TG Therapeutics delivered three compelling presentations, each underscoring the effectiveness and safety profile of BRIUMVI. The data generated enthusiasm among attendees and suggests a promising future for the treatment of MS patients.
Presentation Title: No Association between Decreases in Serum Immunoglobulin and Serious Infections
This presentation by Dr. Bruce Cree from the Weill Institute for Neurosciences at the University of California, San Francisco, discussed the findings indicating that there is no significant correlation between lowered serum immunoglobulin levels and an increased risk of serious infections in patients receiving long-term treatment with BRIUMVI.
Presentation Title: Infusion Tolerability of Ublituximab
Dr. Edward Fox discussed the results of a retrospective evaluation of infusion tolerability in an observational survey called ENAMOR. This study looks at the experiences of patients who received ublituximab infusions, aiming to improve patient comfort during treatments.
Presentation Title: Updates from the ENHANCE Study
Insights from Dr. John Foley were shared regarding the safety and tolerability of 30-minute BRIUMVI infusions. This update from the ENHANCE study focused on refining the infusion process to enhance patient experiences further.
The Importance of BRIUMVI Documentation
Post-presentation, all data will be accessible on the company’s website under the Publications section of the Pipeline. This ongoing commitment to transparency ensures that both healthcare professionals and patients have access to valuable insights regarding treatment options with BRIUMVI.
Insights into the ULTIMATE I & II Trials
The ongoing ULTIMATE I and II trials represent a pivotal phase in the exploration of BRIUMVI as a treatment for RMS. These studies, which are randomized and double-blind, aim to establish the efficacy of BRIUMVI compared to its active comparator, teriflunomide. Participants in these trials have either experienced relapses or demonstrated specific imaging criteria indicative of RMS.
The trials seek to enroll more than a thousand patients across multiple countries, showcasing the substantial interest in advancing the treatment landscape for MS.
Understanding BRIUMVI’s Mechanism
BRIUMVI is a novel monoclonal antibody specifically designed to target CD20-expressing B-cells. This targeted approach is crucial in managing autoimmune disorders like MS. The innovative glycoengineering process allows BRIUMVI to efficiently deplete B-cells at lower dosages, enhancing its therapeutic potential.
What to Know About Patient Safety
Patient safety remains a top priority for TG Therapeutics. The company emphasizes the importance of ongoing monitoring for any potential side effects linked to BRIUMVI, including infusion reactions and infections. Information and guidelines on managing these reactions are readily available, ensuring that healthcare providers are well-equipped to support their patients’ needs.
BRIUMVI Patient Support Program
BRIUMVI Patient Support is a tailored program designed to assist U.S. patients throughout their treatment journey, providing resources and guidance for optimal patient experiences. This initiative reflects TG Therapeutics' commitment to the well-being of their patients and accessibility to necessary treatment.
Frequently Asked Questions
What is BRIUMVI?
BRIUMVI (ublituximab-xiiy) is a monoclonal antibody designed to treat relapsing forms of multiple sclerosis by depleting CD20-expressing B-cells.
Who presented at the CMSC conference?
Three presentations were delivered by Dr. Bruce Cree, Dr. Edward Fox, and Dr. John Foley, highlighting various aspects of BRIUMVI's efficacy and safety.
How does BRIUMVI work?
BRIUMVI targets CD20 on B-cells to effectively deplete these cells, which play a key role in the autoimmune response seen in MS.
Where can I find the presentation data?
The presentation data will be made available on the TG Therapeutics website under the Pipeline section.
What is the ULTIMATE I & II trial?
The ULTIMATE I & II trials are clinical studies comparing BRIUMVI with teriflunomide in patients with relapsing multiple sclerosis.
